<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04238975</url>
  </required_header>
  <id_info>
    <org_study_id>GC3111_P2</org_study_id>
    <nct_id>NCT04238975</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults</brief_title>
  <official_title>Randomized, Double-blind, Active-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of GC3111 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and efficacy (immunogenicity) of a single
      dose of GC3111 versus Boostrix® vaccine among healthy adults in 19-64 years of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate immunogenicity of GC3111 as tetanus, diphtheria and acellular pertussis (Tdap)
      vaccine in healthy adults.

      To evaluate safety of GC3111 in healthy adults.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solicited Adverse Events Following Vaccination with Either GC3111 or Boostrix® Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) to Day 14 (post-vaccination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsolicited Adverse Events Following Vaccination with Either GC3111 or Boostrix® Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) to Day 28 (post-vaccination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events Following Vaccination with Either GC3111 or Boostrix® Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) to Day 180 (post-vaccination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Day 0 (pre-vaccination), Day 28 (post-vaccination)</time_frame>
    <description>Blood Pressure (systolic, diastolic) in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Day 0 (pre-vaccination), Day 28 (post-vaccination)</time_frame>
    <description>Pulse Rate in pulses per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Day 0 (pre-vaccination), Day 28 (post-vaccination)</time_frame>
    <description>Body Temperature in degrees Celcius</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Examinations</measure>
    <time_frame>Screening (pre-vaccination), Day 28 (post-vaccination)</time_frame>
    <description>Blood Test (WBC with differential count (lymphocyte, monocyte etc.), RBC, hemoglobin, hematocrit, platelet count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Examinations</measure>
    <time_frame>Screening (pre-vaccination), Day 28 (post-vaccination)</time_frame>
    <description>Blood Chemistry Test (K, Na, Cl, P, ALT, AST etc.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Examinations</measure>
    <time_frame>Screening (pre-vaccination), Day 28 (post-vaccination)</time_frame>
    <description>Urine Test (pH, specific gravity, bilirubin etc.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of Participants with Antibody Responses (Seroprotection rate) to Tetanus and Diphtheria Components Following Vaccination With Either GC3111 or Boostrix® Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) to Day 28 (post-vaccination)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Participants With Antibody Responses (Boosting Response rate) to Tetanus and Diphtheria Components Following Vaccination With Either GC3111 or Boostrix® Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) to Day 28 (post-vaccination)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMC) for Diphtheria, Tetanus and Acellular Pertussis Antigens</measure>
    <time_frame>Day 28 (post-vaccination)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio (GMR) of Post-vaccination versus Pre-vaccination antibody concentrations for Diphtheria, Tetanus and Acellular Pertussis Antigens</measure>
    <time_frame>Day 0 (pre-vaccination) to Day 28 (post-vaccination)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Functional Antibody Response of Pertussis</measure>
    <time_frame>Day 0 (pre-vaccination) to Day 28 (post-vaccination)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stratified Analysis of Pertussis according to Anti-Pertussis antibody titer (Positive/Negative)</measure>
    <time_frame>Day 0 (pre-vaccination), Day 28 (post-vaccination)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">213</enrollment>
  <condition>Tetanus</condition>
  <condition>Diphtheria</condition>
  <condition>Whooping Cough</condition>
  <arm_group>
    <arm_group_label>GC3111 Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive a single dose of GC3111 vaccine (Biological: GC3111 vaccine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Boostrix® Vaccine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to receive a single dose of Boostrix® vaccine (Biological: Boostrix® vaccine).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC3111 vaccine</intervention_name>
    <description>0.5mL, Intramuscular</description>
    <arm_group_label>GC3111 Vaccine Group</arm_group_label>
    <other_name>GC3111</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Boostrix® vaccine</intervention_name>
    <description>0.5mL, Intramuscular</description>
    <arm_group_label>Boostrix® Vaccine Group</arm_group_label>
    <other_name>Boostrix®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adults aged above 19 and under 64 at the time of screening

          2. Subject without history of administrating vaccines including diphtheria, tetanus or
             whooping cough antigens within 2 years prior to administration of investigational drug

          3. Subject who provided informed consent and assent forms

        Exclusion Criteria:

          1. Subject who received vaccine within 4 weeks prior to receiving study vaccine

          2. Subject who received Tdap vaccine prior to receiving study vaccine

          3. Subject with chronic cough history within 12 weeks before receiving study vaccine

          4. Subject who is pregnant, lactating, or of child bearing potential without using an
             effective method of contraception or not practicing abstinence

          5. Subject who participated in any other clinical study (investigational drug/equipment)
             within 6 months before receiving study vaccine

          6. Subject with any condition that, in the opinion of the Investigator, might interfere
             with the ability to comply with trial procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dah Yoon Kim</last_name>
    <phone>+82-31-260-0976</phone>
    <email>kimdahyoon@greencross.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sujin Lee</last_name>
    <phone>+82-31-260-0870</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Catholic Univ. of Korea Eunpyeong St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

